Document is current
Any future updates will be listed below
-
Authors
Prats, João Antonio Goncalves Garreta
Farsi, Khalil Al
Al-Khabori, Murtadha
Al-Saadawi, Nameer
Alshemmari, Salem H.
Cherif, Honar
Ibrahim, Dima
Kaloyannidis, Panayotis
Swaka, Robert Lodu Serafino Wani
-
Funding
Funding for this research was provided by:
Cogence Health DWC LLC
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 29 January 2026
First Online: 6 February 2026
Declarations
:
: Not applicable.
: Not applicable.
: All authors received honoraria from Cogence Health DWC LLC. Cogence Health DWC LLC received funding from Takeda Pharmaceutical Company Limited (Middle East) to facilitate this project. Dr. J Prats received grants from Merck Sharp & Dohme and consulting fees from Merck Sharp & Dohme, AbbVie, Libbs, and Pfizer, which also support him for attending meetings and/or travel. Additionally, Dr. J Prats received payment/honoraria from Europharma along with those from the other pharmaceutical companies listed above. Dr. M Al-Khabori received honoraria from Novartis, Pfizer, and SOBI. SOBI supports him for attending meetings and/or travel. Dr. N Al-Saadawi received payment/honoraria from Roche and SOBI. BIOLOGIX supports him for attending meetings and/or travel. Dr. S Alshemmari received payment/honoraria from Roche and AstraZeneca, and a research grant from MSD. Begien supports him for attending meetings and/or travel. Dr. D Ibrahim, Dr. H Cherif, Dr. K Al Farsi, Dr. P Kaloyannidis, and Dr. R Swaka have no additional competing interest to declare.
